Logo image of GRFS

GRIFOLS SA-ADR (GRFS) Stock Fundamental Analysis

NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD

8.18  -0.05 (-0.61%)

After market: 8.18 0 (0%)

Fundamental Rating

5

GRFS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. There are concerns on the financial health of GRFS while its profitability can be described as average. GRFS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year GRFS was profitable.
In the past year GRFS has reported a negative cash flow from operations.
In the past 5 years GRFS has always been profitable.
In multiple years GRFS reported negative operating cash flow during the last 5 years.
GRFS Yearly Net Income VS EBIT VS OCF VS FCFGRFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

1.2 Ratios

With an excellent Return On Assets value of 0.73%, GRFS belongs to the best of the industry, outperforming 90.89% of the companies in the same industry.
With an excellent Return On Equity value of 2.67%, GRFS belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
With an excellent Return On Invested Capital value of 3.86%, GRFS belongs to the best of the industry, outperforming 92.50% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GRFS is significantly below the industry average of 15.80%.
The 3 year average ROIC (2.90%) for GRFS is below the current ROIC(3.86%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.73%
ROE 2.67%
ROIC 3.86%
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
GRFS Yearly ROA, ROE, ROICGRFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

GRFS has a better Profit Margin (2.18%) than 91.79% of its industry peers.
GRFS's Profit Margin has declined in the last couple of years.
GRFS's Operating Margin of 16.02% is amongst the best of the industry. GRFS outperforms 95.18% of its industry peers.
GRFS's Operating Margin has declined in the last couple of years.
The Gross Margin of GRFS (38.75%) is better than 74.82% of its industry peers.
In the last couple of years the Gross Margin of GRFS has declined.
Industry RankSector Rank
OM 16.02%
PM (TTM) 2.18%
GM 38.75%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
GRFS Yearly Profit, Operating, Gross MarginsGRFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GRFS is destroying value.
Compared to 1 year ago, GRFS has about the same amount of shares outstanding.
GRFS has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, GRFS has an improved debt to assets ratio.
GRFS Yearly Shares OutstandingGRFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GRFS Yearly Total Debt VS Total AssetsGRFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

GRFS has an Altman-Z score of 1.18. This is a bad value and indicates that GRFS is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.18, GRFS is doing good in the industry, outperforming 69.64% of the companies in the same industry.
GRFS has a Debt/Equity ratio of 1.48. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.48, GRFS is doing worse than 81.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z 1.18
ROIC/WACC0.66
WACC5.85%
GRFS Yearly LT Debt VS Equity VS FCFGRFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 2.66 indicates that GRFS has no problem at all paying its short term obligations.
The Current ratio of GRFS (2.66) is worse than 67.50% of its industry peers.
GRFS has a Quick Ratio of 1.01. This is a normal value and indicates that GRFS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.01, GRFS is doing worse than 87.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.01
GRFS Yearly Current Assets VS Current LiabilitesGRFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 285.83% over the past year.
The earnings per share for GRFS have been decreasing by -23.99% on average. This is quite bad
The Revenue has grown by 9.41% in the past year. This is quite good.
Measured over the past years, GRFS shows a small growth in Revenue. The Revenue has been growing by 7.18% on average per year.
EPS 1Y (TTM)285.83%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%26.88%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%11.66%

3.2 Future

The Earnings Per Share is expected to grow by 17.59% on average over the next years. This is quite good.
Based on estimates for the next years, GRFS will show a small growth in Revenue. The Revenue will grow by 5.43% on average per year.
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y17.59%
Revenue Next Year7.14%
Revenue Next 2Y7.15%
Revenue Next 3Y6.89%
Revenue Next 5Y5.43%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GRFS Yearly Revenue VS EstimatesGRFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
GRFS Yearly EPS VS EstimatesGRFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 31.46, which means the current valuation is very expensive for GRFS.
Compared to the rest of the industry, the Price/Earnings ratio of GRFS indicates a rather cheap valuation: GRFS is cheaper than 94.11% of the companies listed in the same industry.
GRFS is valuated rather expensively when we compare the Price/Earnings ratio to 26.17, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 9.24, the valuation of GRFS can be described as very reasonable.
Based on the Price/Forward Earnings ratio, GRFS is valued cheaply inside the industry as 96.79% of the companies are valued more expensively.
GRFS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31.46
Fwd PE 9.24
GRFS Price Earnings VS Forward Price EarningsGRFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GRFS is valued cheaper than 96.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.05
GRFS Per share dataGRFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GRFS has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GRFS's earnings are expected to grow with 30.46% in the coming years.
PEG (NY)0.75
PEG (5Y)N/A
EPS Next 2Y37.01%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

GRFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRIFOLS SA-ADR

NASDAQ:GRFS (5/28/2025, 8:00:00 PM)

After market: 8.18 0 (0%)

8.18

-0.05 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)07-28 2025-07-28
Inst Owners33.7%
Inst Owner Change3.98%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap5.56B
Analysts73.68
Price Target13.39 (63.69%)
Short Float %1.15%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-66.87%
DP0.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.18%
PT rev (3m)-5.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-13.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-1.28%
Valuation
Industry RankSector Rank
PE 31.46
Fwd PE 9.24
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB N/A
EV/EBITDA 10.05
EPS(TTM)0.26
EY3.18%
EPS(NY)0.89
Fwd EY10.82%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS12.01
BVpS9.8
TBVpS-7.4
PEG (NY)0.75
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 2.67%
ROCE 6%
ROIC 3.86%
ROICexc 4.12%
ROICexgc 9.65%
OM 16.02%
PM (TTM) 2.18%
GM 38.75%
FCFM N/A
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
ROICexc(3y)3.07%
ROICexc(5y)3.33%
ROICexgc(3y)6.89%
ROICexgc(5y)7.47%
ROCE(3y)4.51%
ROCE(5y)4.82%
ROICexcg growth 3Y11.6%
ROICexcg growth 5Y-8.62%
ROICexc growth 3Y14.21%
ROICexc growth 5Y-7.74%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA 6.88
Cap/Depr 56.86%
Cap/Sales 0.83%
Interest Coverage 3.4
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.01
Altman-Z 1.18
F-Score6
WACC5.85%
ROIC/WACC0.66
Cap/Depr(3y)62.1%
Cap/Depr(5y)77.33%
Cap/Sales(3y)1.39%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.83%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%26.88%
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y17.59%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%11.66%
Revenue Next Year7.14%
Revenue Next 2Y7.15%
Revenue Next 3Y6.89%
Revenue Next 5Y5.43%
EBIT growth 1Y60.87%
EBIT growth 3Y27.11%
EBIT growth 5Y0.58%
EBIT Next Year53.59%
EBIT Next 3Y23.7%
EBIT Next 5Y18.42%
FCF growth 1Y-79.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.33%
OCF growth 3YN/A
OCF growth 5YN/A